生化缓解与瞬时弹性成像在监测自身免疫性肝炎病程中的价值
研究纳入60例自身免疫性肝炎(AIH)患者的131次肝活检和125例AIH、130例原发性胆汁性胆管炎(PBC)、100例原发性硬化性胆管炎(PSC)患者的900余次瞬时弹性成像(TE),评估完全生化缓解对组织学活动度和纤维化的影响及重复TE监测价值。AIH组肝硬度(LS)年变化为-6.2%(95%CI -12.6%至-0.2%;p=0.04),完全生化缓解者LS年变化为-7.5%而末缓解者为+1.7%(p<0.001),完全生化缓解是组织学纤维化消退的唯一独立预测因素(相对风险3.66;95%CI 1.54-10.2;p=0.001)。
要点
- AIH患者中完全生化缓解与LS下降相关(缓解者-7.5%/年 vs 未缓解者+1.7%/年,p<0.001)
- 完全生化缓解是组织学纤维化消退的唯一独立预测因素(相对风险3.66;95%CI 1.54-10.2;p=0.001)
- 基线严重纤维化(F4)患者LS下降幅度最大(-11.7%/年;95%CI -19%至-3.5%;p=0.006)
核心结论
- 完全生化缓解是AIH良好预后的可靠预测因素,并导致可通过TE监测的纤维化消退。
研究设计与样本
- 评估60例AIH患者的131次肝活检,以及125例AIH、130例PBC和100例PSC患者的900余次TE。
- TE间隔至少12个月,AIH患者首次TE时已治疗至少6个月。
主要发现
- 与PBC和PSC不同,AIH整个组观察到LS下降(-6.2%/年;95%CI -12.6%至-0.2%;p=0.04)。
- 基线严重纤维化(F4)患者LS下降幅度最大(-11.7%/年;95%CI -19%至-3.5%;p=0.006)。
- 完全生化缓解与LS消退强相关(缓解者-7.5%/年 vs 未缓解者+1.7%/年,p<0.001)。
- 完全生化缓解预测低组织学疾病活动度,且是组织学纤维化消退的唯一独立预测因素(相对风险3.66;95%CI 1.54-10.2;p=0.001)。
- F3/F4纤维化患者中持续生化缓解者组织学随访显示纤维化分期显著下降(3.7±0.5降至1.8±1.7;p=0.007)。
关键数值与推荐
- 完全生化缓解定义为转氨酶和IgG正常化。
临床怎么用
- 作者认为完全生化缓解是AIH良好预后的可靠预测因素,并导致可通过TE监测的纤维化消退。
- 作者认为TE是监测AIH病程的可靠工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver fibrosis regression but also progression may occur in patients with autoimmune hepatitis (AIH) under treatment. There is a need for non-invasive surrogate markers for fibrosis development in AIH to better guide immunosuppressive treatment. The aims of the study were to assess the impact of complete biochemical remission defined as normalisation of aminotransferases and IgG on histological activity and fibrosis development, and the value of repeat transient elastography (TE) measurement for monitoring disease progression in AIH. METHODS: A total of 131 liver biopsies from 60 patients with AIH and more than 900 TE from 125 patients with AIH, 130 with primary biliary cholangitis (PBC) and 100 with primary sclerosing cholangitis (PSC), were evaluated. Time intervals between TE were at least 12 months. Patients with AIH were treated for at least six months at first TE. RESULTS: In contrast to PBC and PSC, a decrease of liver stiffness (LS) was observed in the whole group of patients with AIH (-6.2%/year; 95% CI -12.6% to -0.2%; p = 0.04). The largest decrease of LS was observed in patients with severe fibrosis at baseline (F4: -11.7%/year; 95% CI -19% to -3.5%; p = 0.006). Complete biochemical remission was strongly linked to regression of LS ("remission": -7.5%/year vs. "no remission": +1.7%/year, p <0.001). Similarly, complete biochemical remission predicted low histological disease activity and was the only independent predictor for histological fibrosis regression (relative risk3.66; 95% CI1.54-10.2; p = 0.001). Patients with F3/F4-fibrosis, who remained in biochemical remission showed a considerable decrease of fibrosis stage (3.7 ± 0.5 to 1.8 ± 1.7; p = 0.007) on histological follow-up. CONCLUSIONS: This study demonstrates that complete biochemical remission is a reliable predictor of a good prognosis in AIH and leads to fibrosis regression that can be monitored by TE. LAY SUMMARY: Autoimmune hepatitis is an inflammatory disease of the liver, which often progresses to cirrhosis if left untreated or in the case of insufficient treatment response. Current guidelines have defined biochemical remission (normalisation of biochemical markers for liver inflammation) as a major goal in the treatment of AIH. However, data on the prognostic relevance of this definition are scarce. Herein, we demonstrate that the current definition of biochemical remission is a reliable surrogate for low disease activity on histological assessment and for a beneficial long-term disease course. In addition, we establish transient elastography, a non-invasive ultrasound-based method of measuring scarring of liver tissue, as a reliable tool to monitor disease course in AIH.
引用
- Hartl J, Ehlken H, Sebode M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2017. PMID: 29180000. doi:10.1016/j.jhep.2017.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。